CSPC Pharmaceutical GroupCSPCY +8.17%78 PS Ratio is 3.04 as of Jul. 04, 2026, which is 21% below its 10-year median of 3.83. GuruFocus rates CSPCY with a GF Score™ of 78/100 and a GF Value™ of $3.16 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 950 Drug Manufacturers companies, CSPC Pharmaceutical Group ranks worse than 61.79% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, CSPC Pharmaceutical Group's share price is $3.84.
CSPC Pharmaceutical Group's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $1.26. Hence, CSPC Pharmaceutical Group's PS Ratio for today is 3.04.
The historical rank and industry rank for CSPC Pharmaceutical Group's PS Ratio or its related term are showing as below:
CSPCY'
s PS Ratio Range Over the Past 10 Years
Min: 1.58 Med: 3.83 Max: 9.08
Current: 3.24
During the past 13 years, CSPC Pharmaceutical Group's highest PS Ratio was 9.08. The lowest was 1.58. And the median was 3.83.
CSPCY's PS Ratio is ranked worse than 61.79% of 950
companies
in the Drug Manufacturers industry
Industry Median: 2.315
vs CSPCY: 3.24
CSPC Pharmaceutical Group Ltd revenue per share has been in decline over the past 3 years.
During the past 12 months, the average Revenue per Share Growth Rate of CSPC Pharmaceutical Group was -4.70% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -4.60% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -0.40% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 11.50% per year.
During the past 13 years, CSPC Pharmaceutical Group's highest 3-Year average Revenue per Share Growth Rate was 49.30% per year. The lowest was -50.00% per year. And the median was 14.35% per year.
Back to Basics: PS Ratio
CSPC Pharmaceutical Group (OTCPK:CSPCY) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
CSPC Pharmaceutical Group PS Ratio Related Terms
CSPC Pharmaceutical Group PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, CSPC Pharmaceutical Group's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CSPC Pharmaceutical Group PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, CSPC Pharmaceutical Group's PS Ratio distribution charts can be found below:
* The bar in red indicates where CSPC Pharmaceutical Group's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
CSPC Pharmaceutical Group's Share Price of today is $3.84. CSPC Pharmaceutical Group's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.26.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
CSPC Pharmaceutical Group (CSPCY) has a PS Ratio of 3.04 as of Jul. 04, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on CSPC Pharmaceutical Group and its competitors. This is 21% below median its historical median of 3.83. Over the past decade, CSPC Pharmaceutical Group's PS Ratio has ranged from 1.58 to 9.08. According to the industry distribution chart, CSPC Pharmaceutical Group ranks #587 out of 950 companies in the Drug Manufacturers industry, placing it in the top 61.8%.
Is CSPC Pharmaceutical Group's PS Ratio too high?
CSPC Pharmaceutical Group's current PS Ratio of 3.04 is 21% below median its 10-year median of 3.83. Over the past 10 years, this metric has ranged from a low of 1.58 to a high of 9.08. The Drug Manufacturers industry median PS Ratio is 2.32. CSPC Pharmaceutical Group's value of 3.04 is 31.3% above this industry median. Based on the distribution chart, CSPC Pharmaceutical Group ranks #587 out of 950 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, CSPC Pharmaceutical Group has a GF Score™ of 78/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CSPC Pharmaceutical Group's PS Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, CSPC Pharmaceutical Group ranks #587 out of 950 companies for PS Ratio. This places CSPC Pharmaceutical Group in the lower half of its industry. The industry median PS Ratio is 2.32. CSPC Pharmaceutical Group's value of 3.04 is 31.3% above this benchmark. Historically, CSPC Pharmaceutical Group's own PS Ratio has ranged from 1.58 to 9.08 over the past decade. While the company's 10-year median is 3.83 vs. the industry median of 2.32, CSPC Pharmaceutical Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.32, based on 950 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CSPC Pharmaceutical Group's current PS Ratio of 3.04 is 31.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on CSPC Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CSPC Pharmaceutical Group's current PS Ratio is 3.04, which is 21% below median its own 10-year median of 3.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSPC Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, CSPC Pharmaceutical Group (CSPCY) is currently considered Modestly Overvalued. The stock's GF Value™ is $3.16, compared to a current price of $3.84 — trading 21.5% above its estimated fair value. The current PS Ratio is 3.04, which is 21% below median its 10-year median of 3.83 and 31.3% above the Drug Manufacturers industry median of 2.32. CSPC Pharmaceutical Group's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For CSPC Pharmaceutical Group (CSPCY), the current PS Ratio is 3.04 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CSPC Pharmaceutical Group (CSPCY) Overvalued in 2026?
Based on GuruFocus' analysis, CSPC Pharmaceutical Group stock appears to be overvalued.
The current stock price of $3.84 is trading 21.5% above its estimated GF Value™ of $3.16.
GuruFocus considers CSPC Pharmaceutical Group to be Modestly Overvalued.
Key valuation signals for CSPCY:
PS Ratio: 3.04 (21% below median its 10-year median of 3.83)
GF Value™: $3.16 vs. price of $3.84 (21.5% above fair value)
Industry Position: 31.3% above the Drug Manufacturers median (#587 of 950)
No single metric tells the full story. See the CSPCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CSPC Pharmaceutical Group LTD is engaged in the manufacture and sale of pharmaceutical products. The group's segments include: Finished drugs, consisting research and development, manufacture and sale of pharmaceutical products and license fee income; Bulk products, that manufacture and sale of vitamin C, and antibiotic products in bulk powder form; and Functional food and others, that manufacture and sale of functional food products (including caffeine food additives, anhydrous glucose, acarbose and vitamin C buccal tablets), provision of healthcare service and others. It derives maximum revenue from Finished Products segments. Geographically, the company operates in Chinese Mainland, which Chinese Mainland generates maximum revenue; Other Asian regions; Europe; North America; and Others.
78GF Score
Get the complete analysis for CSPCY
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSPCY has been successfully added to your 
